Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus LA02
- Development stage
- Unknown
- Lead developer
- Probiotical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
Lactobacillus acidophilus LA02 is a specific probiotic bacterial strain (deposited as DSM 21717) developed by the Italian company Probiotical S.p.A. It is a Gram-positive, lactic acid-producing bacterium characterized by its ability to survive gastrointestinal transit and adhere to mucosal surfaces. LA02 has been clinically evaluated for its role in maintaining and restoring healthy microbial populations in the gut and vaginal environments. Specifically, it has been studied for the prevention of recurrent vulvovaginal candidiasis (VVC) due to its antagonistic activity against Candida species, often delivered via specialized slow-release vaginal tablets. Additionally, research has explored its potential systemic effects on cognitive function and metabolic health (weight loss) when administered orally, frequently in combination with other probiotic strains such as Bifidobacterium lactis BS01.
- Other names
- Lactobacillus acidophilus LA02-ID-1688L. acidophilus LA02
Beyond the preview
Go deeper on lactobacillus acidophilus LA02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus LA02.